EA201992360A1 - Кристаллические формы (s)-афоксоланера - Google Patents

Кристаллические формы (s)-афоксоланера

Info

Publication number
EA201992360A1
EA201992360A1 EA201992360A EA201992360A EA201992360A1 EA 201992360 A1 EA201992360 A1 EA 201992360A1 EA 201992360 A EA201992360 A EA 201992360A EA 201992360 A EA201992360 A EA 201992360A EA 201992360 A1 EA201992360 A1 EA 201992360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline forms
afoxolaner
methods
compositions
preparing
Prior art date
Application number
EA201992360A
Other languages
English (en)
Russian (ru)
Inventor
Ролоф Йоан Горте Де Ври
Брюно Байон
Сильвен Лафон
Мириам Ге Де Сен Мишель
Стефан Козлович
Original Assignee
БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. filed Critical БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК.
Publication of EA201992360A1 publication Critical patent/EA201992360A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Secondary Cells (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201992360A 2017-04-05 2018-04-05 Кристаллические формы (s)-афоксоланера EA201992360A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482175P 2017-04-05 2017-04-05
PCT/US2018/026328 WO2018187623A1 (en) 2017-04-05 2018-04-05 Crystalline forms of (s)-afoxolaner

Publications (1)

Publication Number Publication Date
EA201992360A1 true EA201992360A1 (ru) 2020-09-02

Family

ID=62092252

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992360A EA201992360A1 (ru) 2017-04-05 2018-04-05 Кристаллические формы (s)-афоксоланера

Country Status (23)

Country Link
US (2) US10662163B2 (de)
EP (1) EP3606911A1 (de)
JP (1) JP7222909B2 (de)
KR (1) KR102612648B1 (de)
CN (1) CN111032634A (de)
AR (1) AR111412A1 (de)
AU (1) AU2018250304B2 (de)
BR (1) BR112019021072A2 (de)
CA (1) CA3059114A1 (de)
CL (1) CL2019002840A1 (de)
CO (1) CO2019011980A2 (de)
EA (1) EA201992360A1 (de)
IL (1) IL269792B (de)
MD (1) MD20190080A2 (de)
MX (1) MX2019011931A (de)
MY (1) MY188420A (de)
PH (1) PH12019502277A1 (de)
SG (1) SG11201909229SA (de)
TW (1) TWI782976B (de)
UA (1) UA125727C2 (de)
UY (1) UY37665A (de)
WO (1) WO2018187623A1 (de)
ZA (1) ZA201906464B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909229SA (en) * 2017-04-05 2019-11-28 Boehringer Ingelheim Animal Health Usa Inc Crystalline forms of (s)-afoxolaner
WO2021254445A1 (zh) * 2020-06-19 2021-12-23 东莞市东阳光仿制药研发有限公司 一种gaba抑制剂的晶型及其制备方法
CN118536571A (zh) * 2024-05-31 2024-08-23 北京无问芯穹科技有限公司 一种构建扩散变换器模型的方法、系统、设备及存储介质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
TWI649303B (zh) * 2007-08-17 2019-02-01 杜邦股份有限公司 製備4-乙醯基-n-〔2-側氧基-2-〔(2,2,2-三氟乙基)胺基〕乙基〕-1-萘甲醯胺之化合物及方法
MA34247B1 (fr) 2010-05-27 2013-05-02 Du Pont Forme cristalline du 4-[5-[3-chloro-5-(trifluorométhyl) phényl] -4,5-dihydro-5-(trifluorométhyl)-3-isoxazolyl]-n-[2-oxo-2-[(2, 2,2-trifluoroéthyl) amino] éthyl]-1-naphtalènecarboxamide
DK3172964T3 (da) * 2011-09-12 2020-11-30 Boehringer Ingelheim Animal Health Usa Inc Parasitiske sammensætninger indeholdende et isoxazolinaktivstof, fremgangsmåde og anvendelser deraf
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
JP2015028006A (ja) * 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法
UY36570A (es) * 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
KR102593069B1 (ko) * 2015-04-08 2023-10-23 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 이속사졸린 활성제를 포함하는 서방형 주사 제형, 이의 방법 및 용도
MX2020013754A (es) 2016-04-06 2022-07-25 Boehringer Ingelheim Animal Health Usa Inc Proceso para preparar compuestos de isoxazolina.
SG11201909229SA (en) * 2017-04-05 2019-11-28 Boehringer Ingelheim Animal Health Usa Inc Crystalline forms of (s)-afoxolaner

Also Published As

Publication number Publication date
JP7222909B2 (ja) 2023-02-15
AU2018250304B2 (en) 2022-03-03
KR20190136055A (ko) 2019-12-09
US11130739B2 (en) 2021-09-28
KR102612648B1 (ko) 2023-12-11
IL269792A (en) 2019-11-28
CL2019002840A1 (es) 2020-01-10
WO2018187623A8 (en) 2019-10-24
UA125727C2 (uk) 2022-05-25
PH12019502277A1 (en) 2020-09-14
US20180354917A1 (en) 2018-12-13
MD20190080A2 (ro) 2020-04-30
EP3606911A1 (de) 2020-02-12
US20200270219A1 (en) 2020-08-27
AU2018250304A1 (en) 2019-10-31
CN111032634A (zh) 2020-04-17
MY188420A (en) 2021-12-08
ZA201906464B (en) 2021-08-25
SG11201909229SA (en) 2019-11-28
TWI782976B (zh) 2022-11-11
IL269792B (en) 2022-04-01
TW201841895A (zh) 2018-12-01
UY37665A (es) 2018-10-31
AR111412A1 (es) 2019-07-10
US10662163B2 (en) 2020-05-26
BR112019021072A2 (pt) 2020-05-12
JP2020513010A (ja) 2020-04-30
MX2019011931A (es) 2020-01-13
CO2019011980A2 (es) 2020-02-18
WO2018187623A1 (en) 2018-10-11
CA3059114A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
PH12018500457A1 (en) New phenoxymethyl derivatives
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201892147A1 (ru) Бициклические соединения
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX2016011992A (es) Derivados de piperidina-diona.
EA201792021A1 (ru) Ингибитор jak
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
EA201790570A1 (ru) Модуляторы р2х7